Alnylam Pharmaceuticals I... (ALNY)
Alnylam Pharmaceuticals Inc. (ALNY) Stock Price, Analysis & Data
| Bid | 221.6 |
| Market Cap | 30.59B |
| Revenue (ttm) | 4.8B |
| Net Income (ttm) | 774.71M |
| Beta | 0.28 |
| EPS (ttm) | 5.75 |
| PE Ratio (ttm) | 39.76 |
| Forward PE | 18.16 |
| P/B (ttm) | 22.58 |
| P/S (ttm) | 6.37 |
| Earnings Date | Oct 29, 2026 |
| Ask | 226.3 |
| Volume | 1,600,221 |
| Avg. Volume (20D) | 1,655,311 |
| Open | 226.00 |
| Previous Close | 224.60 |
| Day's Range | 222.01 - 230.91 |
| 52-Week Range | 197.81 - 495.55 |
| Analyst | Buy |
| Price Target | 350 (53.10%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxalu...
Financial Performance
In 2025, Alnylam Pharmaceuticals's revenue was 3.71B, an increase of 65.19% compared to the previous year's 2.25B. Earnings were 313.75M, a decrease of -212.79%.
Financial StatementsAnalyst Forecast
According to 25 analyst ratings, the average rating for ALNY stock is "Buy". The 12-month stock price forecast is 350, which is upside of 53.1% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
